This table lists the meeting dates and topics that have been discussed at the Arthritis Advisory Committee of the FDA. To get information on a topic, first click on the year, then find the date that the topic was discussed. For more information on advisory committees, please see http://www.fda.gov/cder/audiences/acspage/
| Year |
Date |
Topic |
| 2008 |
July 29, 2008 |
Actemra (tocilizumab) |
| 2007 |
April 12, 2007 |
Arcoxia (etoricoxib) Osteoarthritis |
| 2006 |
November 29 |
Celebrex (celecoxib) for JRA |
| 2005 |
February 16-18 |
COX-2/NSAID safety |
| September 6 |
Orencia (abatacept) for RA |
| 2004 |
June 2 |
Gout: chronic (oxypurinol) |
| June 3 |
Gout: acute (arcoxia) |
| 2003 |
March 4 |
TNF safety update (TB, lymphoma, hepatic, CHF) |
| March 5 |
Arava (Leflunomide): Citizen’s Petition and physical function |
| June 23 |
Fibromyalgia: Claims |
| June 24 |
Enbrel (etanercept) for AS |
| September 29 |
SLE guidance (Claims) |
| September 30 |
SLE guidance (Trial design) |
| 2002 |
July 29-30 |
Pain |
| 2001 |
February 7 |
Celebrex (celecoxib): CLASS study |
| February 8 |
Vioxx (rofecoxib): VIGOR study |
| April 19 |
Aslera (prasterone) for SLE |
| August 16 |
Anakinra (Kineret) for RA |
| August 17 |
TNF inhibitor (Enbrel, Remicade): Safety update |
| 2000 |
April 11 |
Enbrel (etanercept) for early RA, disease modification |
| July 12 |
Remicade (infliximab) for structural benefit, physical function |
| 1999 |
February 23 |
Trial designs for SLE |
| April 20 |
Vioxx (rofecoxib) for OA, RA |
| July 20 |
Flexeril (cyclobenzaprine) for OTC use |
| July 21 |
Disease modification in OA |
| 1998 |
March 24 |
NSAID-COX-2 safety |
| August 7 |
Arava (leflunomide) for RA |
| September 16 |
Enbrel (etanercept) for RA, JRA |
| December 1 |
Celebrex (celecoxib) for OA, RA |
| 1997 |
February 4 |
Neoral (cyclosporine) for RA |
| February 5 |
RA guidance |
| May 6-7 |
Annual update |
| July 15 |
Excedrin ES (OTC and Rx) |
